関連する実験動画

Updated: May 5, 2026

Intranasal Administration of CNS Therapeutics to Awake Mice
07:15

Intranasal Administration of CNS Therapeutics to Awake Mice

Published on: April 8, 2013

59.8K

鼻内投与によるアルツハイマー病の併用療法のための単一分子性基架

Jian-Mei Gao1, Wen-Bo Li2, Na-Na Chen1,3

  • 1School of Pharmacy, Key Laboratory of Basic Pharmacology of Ministry of Education and Joint International Research Laboratory of Ethnomedicine of Ministry of Education, Zunyi Medical University, Zunyi, 563000, China.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)
|August 27, 2025
PubMed
まとめ

グアニジニウム改変カリックス[5]アレン (GC5AY) の新型エスカフォードは神経保護剤トリロバチン (TLB) を鼻内投与する. この併用療法では,血液脳障壁 (BBB) を回避することで,マウスのアルツハイマー病 (AD) の症状を効果的に治療します.

キーワード:
アルツハイマー病併用療法鼻内投与マクロサイクル宿主超分子材料

さらに関連する動画

Intranasal Delivery of Therapeutic Stem Cells to Glioblastoma in a Mouse Model09:57

Intranasal Delivery of Therapeutic Stem Cells to Glioblastoma in a Mouse Model

Published on: June 4, 2017

12.3K
A Positioning Device for the Placement of Mice During Intranasal siRNA Delivery to the Central Nervous System05:28

A Positioning Device for the Placement of Mice During Intranasal siRNA Delivery to the Central Nervous System

Published on: August 15, 2019

23.9K

関連する概念動画

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.7K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.3K
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
29
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and...
42